Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings.
Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year that was below market expectations.The stock was down 0.2% Wednesday while the S&P 500 futures was up 0.
Abbott Laboratories stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks Consensus Estimate. However, the figure improved 12.6% from the prior-year quarter’s level.
Abbott: Q4 Earnings Snapshot
The average estimate of nine analysts surveyed by Zacks Investment Research was also for earnings of $1.34 per share. The maker of infant formula, medical devices and drugs posted revenue of $10.97 billion in the period,
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session,
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.
Abbott Laboratories Reports Strong 2024 Financial Results
Abbott Laboratories ( ($ABT) ) has released its Q4 earnings. Here is a breakdown of the information Abbott Laboratories presented to its
Earnings call transcript: Abbott Labs Q3 2024 sees steady growth
Abbott Laboratories (NYSE:ABT) reported its Q3 2024 earnings, meeting EPS expectations while slightly missing revenue forecasts. The company posted an EPS of $1.34, aligning with analysts' predictions,
Abbott's first-quarter profit forecast misses estimates, shares dip
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...
Abbott Laboratories: Solid Performance in Key Sectors but Hold Rating Due to Mixed Outlook
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
bovnews1d
Abbott’s (ABT) Impressive Q4 and Bold Projections for 2025: What You Need to Know
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
Abbott Laboratories: Strong Performance and Promising Outlook Support Buy Rating
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...
Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update
For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.
Abbott banks on glucose monitors, new launches to ride out China, currency hit
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street estimates, along with weak fourth-quarter ...
Abbott’s First-Quarter Outlook Misses Estimates, Shares Down
Abbott Laboratories is forecasting lower-than-expected first-quarter earnings but full-year profit in line with Wall Street ...
Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit
Abbott stock fell early Wednesday after the health giant narrowly missed fourth-quarter sales views and reported in-line ...